Anbio Biotechnology (NNNN) Non-Current Assets (2023 - 2024)

Anbio Biotechnology's quarterly Non-Current Assets came in at $387440.0 in Q4 2024, up 523.53% year-on-year from $62137.0 in Q1 2024, and up 523.53% quarter-over-quarter from $62137.0 in Q4 2023.

Anbio Biotechnology has reported Non-Current Assets for 2 years, with the latest figure at $387440.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn 11.30 Bn
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn 42.82 Bn
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn 4.72 Bn
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn 2.28 Bn
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn 10.51 Bn
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn 10.29 Bn
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn 3.66 Bn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn 13.00 Bn
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn 3.33 Bn
10 Anbio Biotechnology 1.32 Bn 1.31 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 387,440.00
Dec 31, 2023 62,137.00